IP Library › Granted Patent US 12,134,594
Granted Patent B2
US 12,134,594 · App. 17/209,337 · Granted Nov 5, 2024

Composition and application thereof as antitumor drug

Inventors: Xiaojiang Tang (Guangzhou, CN); Xuefeng Ren (Guangzhou, CN); Yichen Ge (Guangzhou, CN); Zhiyong Zhong (Guangzhou, CN); Nina Zheng (Flushing, NY)
Assignee: Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.
C07C333/04A61K33/243A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,134,594
App. No.
17/209,337
Granted
Nov 5, 2024
Kind
B2
Abstract

A composition is prepared from a platinum-based antitumor compound and a novel compound, and the novel compound is sodium(S)-2-(dithiocarboxylate ((2S, 3R, 4R, 5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-4-(methylthio)butyrate. The novel compound in the composition could effectively chelate the platinum-based antitumor compound and reduce the various adverse effects exhibited by the platinum-based compound. The dosage of the platinum-based antitumor compound can thus be increased, and the antitumor effect can be optimized. The novel compound itself is low-toxic and it has low chelating activities with essential metals in the human body; it would not impose significant adverse effects on the human body at given doses. The composition and its application as an antitumor drug overcome some technical drawbacks of platinum-based antitumor drugs, namely severe adverse effects and the development of drug resistance during administration.

Claims (8)

1. A method of treating solid tumors in a subject suffering from cancer, including:

administering a drug to the subject, wherein the drug comprises, in parts by mole, 1-5 parts of a platinum-based antitumor compound and 1-50 parts of sodium (S)-2-(dithiocarboxylate ((2S,3R,4R),5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-4-(methylthio)butyrate (GMDTC).

2. The method according to claim 1 , wherein the platinum-based antitumor compound is one or more selected from the group consisting of cisplatin, oxaliplatin, and carboplatin.

3. The method according to claim 2 , wherein the platinum-based antitumor compound is cisplatin.

4. The method according to claim 1 , wherein the drug comprises, in parts by mole, 1-3 parts of the platinum-based antitumor compound and 1-20 parts of GMDTC.

5. The method according to claim 4 , wherein the drug comprises, in parts by mole, 1 part of the platinum-based antitumor compound and 20 parts of GMDTC.

6. The method according to claim 1 , wherein GMDTC is administered 2 hours after administration of cisplatin.

7. The method according to claim 1 , wherein the cancer is breast cancer.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ADD THE 5TH INVENTOR PREVIOUSLY RECORDED AT REEL: 55726 FRAME: 663. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 15, 2024
From: TANG, XIAOJIANG; REN, XUEFENG; GE, YICHEN; ZHONG, ZHIYONG; ZHENG, NINA
To: GUANGDONG ZHONGERJIAN BIOTECHNOLOGY CO., LTD.; TANG, XIAOJIANG
Reel/Frame 066613/0620 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2023
From: GUANGDONG ZHONGERJIAN BIOTECHNOLOGY CO., LTD.; TANG, XIAOJIANG
To: GUANGDONG JIANERSHENG PHARMACEUTICAL TECHNOLOGY CO., LTD.
Reel/Frame 065654/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2021
From: TANG, XIAOJIANG; REN, XUEFENG; GE, YICHEN; ZHONG, ZHIYONG
To: GUANGDONG ZHONGERJIAN BIOTECHNOLOGY CO., LTD.; TANG, XIAOJIANG
Reel/Frame 055726/0663 →
Priority Claims (1)
CN 201811185272.8 · Oct 11, 2018 · national
Continuity (2)
Continuation In Part PCTCN2019087023 · May 15, 2019
Related Publication 20210276948A1 · Sep 9, 2021